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ABSTRACT
This study presents the results of a survey of the in-vitro susceptibility to antimicrobial agents of major
pathogens responsible for community-acquired respiratory tract infections in Poland during 2002–2004.
The collection of 1184 bacterial isolates comprised 398 Streptococcus pneumoniae, 344 Haemophilus
inﬂuenzae, 302 Streptococcus pyogenes and 140 Moraxella catarrhalis. Among the pneumococcal isolates,
16.8% were penicillin-non-susceptible (PNSP), of which 80.6% were identiﬁed as multidrug-resistant.
Overall, 9.0% of H. inﬂuenzae isolates were b-lactamase-positive, although this percentage increased
noticeably in the third year of the study. Based on PCR results, 12.8% of H. inﬂuenzae isolates were
identiﬁed as low-level b-lactamase-negative, ampicillin-resistant (BLNAR), and one isolate as low-level
b-lactamase-positive, amoxycillin–clavulanic acid-resistant (BLPACR). Pulsed-ﬁeld gel electrophoresis
(PFGE) classiﬁed 45 H. inﬂuenzae isolates with altered penicillin-binding proteins into 15 PFGE types,
including two predominant types (with four and six sub-types) containing 15 and ten isolates,
respectively. Resistance to tetracycline, erythromycin and clindamycin was found in 20.9%, 8.9% and
4.6% of S. pyogenes isolates, respectively. The production of b-lactamase characterised 91.4% of
M. catarrhalis isolates. In summary, the overall occurrence of PNSP in Poland remains stable, although
there was a noticeable increase in the proportion of fully-resistant isolates. A rising trend in the
prevalence of b-lactamase producers and low-level BLNAR isolates was observed among Polish isolates
of H. inﬂuenzae.
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INTRODUCTION
Community-acquired respiratory tract infections
represent one of the major causes of morbidity
and mortality worldwide, and remain the most
frequent reason for prescription of antibiotics to
non-hospitalised patients. Haemophilus inﬂuenzae,
Streptococcus pneumoniae and Moraxella catarrhalis
are the most common bacterial aetiological agents
of typical lower respiratory tract infections
(LRTIs), whereas Streptococcus pyogenes is most
commonly responsible for acute pharyngitis [1,2].
Microbiological investigations to guide treatment
are often time-consuming and are not feasible for
every patient. In addition, the resistance patterns
of the major LRTI pathogens differ and may
change dramatically over time. This is a major
concern with respect to the appropriate selection
of antibiotics for empirical therapy. It has also
been observed that the prevalence of multidrug-
resistant strains varies geographically [3]. There-
fore, in order to select the optimal antimicrobial
treatment regimen, it is necessary to know the
local susceptibility patterns of the most common
pathogens responsible for a particular type of
infection. The present study describes the
results of a surveillance of the in-vitro suscepti-
bility to antimicrobial agents of major pathogens
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responsible for community-acquired respiratory
tract infections in Poland during 2002–2004. This
study constitutes a follow-up at the national level
of the international Alexander Project, which
ceased at the end of 2001 [3].
MATERIALS AND METHODS
The study protocol anticipated the collection of 400 isolates per
year belonging to four species, namely H. inﬂuenzae, S. pneu-
moniae, M. catarrhalis and S. pyogenes, with at least 100 isolates
of S. pneumoniae and 100 isolates of H. inﬂuenzae. Between 1
January 2002 and 31 December 2004, 1184 isolates were
collected, comprising 398 S. pneumoniae, 344 H. inﬂuenzae, 302
S. pyogenes and 140 M. catarrhalis. More than 94% of the
isolates (n = 1121) were collected from 19, 11, 18 and ﬁve
centres, respectively, representing all the regions of Poland.
The remaining isolates were from centres that sent fewer than
three isolates. Except for patients with infections caused by
S. pyogenes, the study included isolates from both outpatients
and hospitalised patients with clinically-proven community-
acquired LRTIs (acute exacerbations of chronic bronchitis or
pneumonia), with sampling undertaken for the hospitalised
patients within 48 h of admission. The samples investigated
included sputum (evaluated by the numbers of white blood
cells, epithelial cells, and the presence of mucus threads),
bronchoalveolar lavage ﬂuid or blood [4]. S. pyogenes isolates
were isolated from the throat swab cultures of patients with
acute pharyngitis ⁄ tonsillitis. Only one isolate per patient was
included in the study. All isolates were identiﬁed to the species
level according to standard procedures [5].
For H. inﬂuenzae, S. pneumoniae and S. pyogenes, MICs of
appropriate antibiotics (see Results) were determined by broth
microdilution tests and interpreted according to CLSI guide-
lines [6]. Additionally, for pneumococci resistant to cipro-
ﬂoxacin (MIC ‡4 mg ⁄L) [7,8], the MICs of levoﬂoxacin and
moxiﬂoxacin and, for isolates resistant to macrolides, the MIC
of telithromycin, were determined. All erythromycin-resistant
S. pyogenes isolates were assigned to speciﬁc phenotypes, i.e.,
constitutive MLSB (cMLSB), inducible MLSB (iMLSB) and
efﬂux-mediated resistance (M phenotype) on the basis of
double-disk tests with clindamycin and erythromycin (2-lg
and 15-lg disks, respectively) [6]. Fisher’s exact test was used
to analyse the differences in susceptibility frequencies.
Production of b-lactamase by H. inﬂuenzae and M. catarrh-
alis isolates was determined with the nitroceﬁn assay, used
according to the manufacturer’s instructions (Becton
Dickinson, Meylan, France). Quality control strains used for
antimicrobial susceptibility testing during this study were
H. inﬂuenzae ATCC 49247, ATCC 49766 and ATCC 10211, and
S. pneumoniae ATCC 49619.
PCR assays were performed for H. inﬂuenzae isolates with
ampicillin MICs ‡1 mg ⁄L and ⁄ or amoxycillin–clavulanic acid
MICs ‡1 mg ⁄L and ⁄ or elevated cephalosporin MICs in order
to identify isolates with altered penicillin-binding proteins
(PBPs). Such isolates can be classiﬁed as b-lactamase-negative,
ampicillin-resistant (BLNAR), low-level BLNAR, b-lactamase-
positive, amoxycillin–clavulanic acid-resistant (BLPACR), and
low-level BLPACR, depending on resistance level, mutation
types and concomitant production of b-lactamase. In brief,
primer pairs O1 ⁄O3, HI-1 ⁄HI-2, PBP3S-S ⁄PBP3S-R and
PBP3BLN-S ⁄PBP3BLN-R were used to produce amplicons
characteristic of H. inﬂuenzae, capsule production, b-lactamase-
negative, ampicillin-susceptible (BLNAS) isolates and BLNAR
isolates, respectively [9–11]. Isolates yielding a PCR product
only with the ﬁrst pair, or the ﬁrst two pairs, of primers were
identiﬁed as low-level BLNAR [11]. For isolates that yielded
speciﬁc products for capsule genes, PCRs to identify serotypes
a–f were performed with primers a1 ⁄ a2, b1 ⁄ b2, c1 ⁄ c2, d1 ⁄d2,
e1 ⁄ e2 and f1 ⁄ f2, respectively [9]. In this study, the term
‘ampicillin-resistant’ will be used in relation to low-level
BLNAR or low-level BLPACR isolates, despite their in-vitro
susceptibility to this antibiotic according to CLSI criteria [6].
The relatedness among H. inﬂuenzae isolates with altered PBPs
was evaluated by restriction fragment length polymorphism
analysis of SmaI-digested chromosomal DNA using pulsed-
ﬁeld gel electrophoresis (PFGE), and was interpreted as
described previously [12,13].
RESULTS
The isolates responsible for LRTI, mostly from
adult patients, were recovered mainly from spu-
tum (74.4%, n = 656), followed by bronchoalveo-
lar lavage ﬂuid (18.0%, n = 159) and blood (7.6%,
n = 67). All S. pyogenes isolates were obtained
from throat swabs (n = 302). Clinical and demo-
graphical data of the patients included in the
study are summarised in Table 1.
Table 1. Numbers of isolates of Streptococcus pneumoniae,
Haemophilus inﬂuenzae, Moraxella catarrhalis and Streptococ-
cus pyogenes, grouped according to diagnosis, specimen
type, service, gender and age during the period 2002–2004
S. pneumoniae
(n = 398)
H. inﬂuenzae
(n = 344)
M. catarrhalis
(n = 140)
S. pyogenes
(n = 302)
No. of isolates ⁄ year
2002 ⁄ 2003 ⁄ 2004 137 ⁄ 118 ⁄ 143 128 ⁄ 115 ⁄ 101 47 ⁄ 33 ⁄ 60 46 ⁄ 163 ⁄ 93
Diagnosis
AECB 136 219 109 0
Pneumonia 191 83 17 0
Pharyngitis ⁄ tonsillitis 0 0 0 302
Unspeciﬁed LRTI 71 42 14 0
Specimen
Sputum 255 278 123 0
BAL 85 58 16 0
Blood 58 8 1 0
Throat swab 0 0 0 302
Service
Inpatient 275 239 108 61
Outpatient 81 39 17 68
Unknown 42 66 15 173
Gender
Female 112 100 50 154
Male 266 238 88 114
Unspeciﬁed 20 6 2 34
Age group (years)
£16 47 17 8 138
17–30 27 17 3 54
31–45 33 29 8 47
46–60 97 84 31 11
61–75 120 132 59 6
>75 61 60 30 1
Unknown 13 5 1 45
AECB, acute exacerbations of chronic bronchitis; BAL, bronchoalveolar lavage;
LRTI, lower respiratory tract infection.
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S. pneumoniae
The in-vitro antimicrobial susceptibilities and
MIC50 ⁄MIC90 values for 398 S. pneumoniae isolates
are shown in Table 2. In total, 16.8% were non-
susceptible to penicillin (penicillin non-suscept-
ible pneumococci; PNSP), with 5.0% (n = 20) of
isolates being intermediately-susceptible to peni-
cillin (MIC 0.12–1.0 mg ⁄L), and 11.8% (n = 47)
being penicillin-resistant pneumococci (PRP)
(MIC ‡ 2 mg ⁄L). During the 3-year study period,
the proportion of PNSP remained at a similar
level, with 17.5% in 2002, 16.1% in 2003, and
16.8% in 2004. However, among the isolates of
PNSP, the proportion of PRP was higher in the
second (78.9%; p 0.06) and third (83.3%; p 0.03)
years than in the ﬁrst year (50%) of the study.
All penicillin-susceptible pneumococci were
also susceptible to amoxycillin and ceftriaxone.
Only two isolates were resistant to cefuroxime,
and two and three isolates were resistant and
intermediately-susceptible, respectively, to cefa-
clor. All penicillin intermediately-susceptible iso-
lates were fully-susceptible only to amoxycillin.
Except for two isolates, erythromycin-resistant
pneumococci were always resistant to azithromy-
cin and clarithromycin. Noteworthy differences in
susceptibility to anti-pneumococcal drugs were
observed among isolates of penicillin-susceptible
pneumococci and PNSP (Table 2). Among PNSP,
80.6% of isolates were multidrug-resistant, i.e.,
resistant at least to three groups of antibiotics,
most frequently including co-trimoxazole, tetra-
cyclines, macrolides and various generations of
cephalosporins. Resistance to ciproﬂoxacin was
found in 26 (6.6%) isolates, all of which were
susceptible to moxiﬂoxacin, and all but two of
which were susceptible to levoﬂoxacin, with
MICs ranging from 0.06 to 0.25 mg ⁄L and from
1.0 to 4.0 mg ⁄L, respectively. Among pneumo-
cocci resistant to erythromycin (n = 54), three had
intermediate resistance to telithromycin, with
MICs of 2.0 mg ⁄L.
H. inﬂuenzae
The results of susceptibility testing of H. inﬂuen-
zae isolates are summarised in Table 3. All
H. inﬂuenzae isolates were susceptible to amoxy-
cillin–clavulanic acid, ceftriaxone, ciproﬂoxacin,
azithromycin and chloramphenicol, whereas
92.4%, 97.4% and 58.1% were susceptible to
clarithromycin, tetracycline and co-trimoxazole,
respectively. Of 344 isolates, 31 (9.0%) were
identiﬁed as b-lactamase-positive, amoxycillin-
resistant (BLPAR). During the ﬁrst 2 years of the
study (2002–2003), the proportions of BLPAR
isolates were similar, i.e., 6.3% and 5.2%, respect-
ively. However, this percentage increased notice-
ably to 16.8% in 2004.
In total, 123 isolates met the criteria required for
further testing for altered PBPs. Of these, 44
(12.8% of all H. inﬂuenzae isolates) were identiﬁed
as non-typeable low-level BLNAR isolates, based
on the PCR assay used. One isolate of serotype b
(Hib) possessed two mechanisms of b-lactam
resistance, being both a b-lactamase producer
and having changes in PBPs (BLPACR). The
proportion of isolates with modiﬁed PBPs during
the ﬁrst year of the study was 7.8%, and this
Table 2. In-vitro activities of antibiotics against Streptococcus pneumoniae isolates
Antibiotic
All isolates (n = 398) PSP (n = 331) PIP (n = 20) PRP (n = 47)
%I %R MIC50 ⁄MIC90a %I %R MIC50 ⁄MIC90a %I %R MIC50 ⁄MIC90a %I %R MIC50 ⁄MIC90a
Penicillin 5.0 11.8 0.015 ⁄ 2.0 0 0 0.015 ⁄ 0.015 100 0 0.25 ⁄ 1.0 0 100 2.0 ⁄ 8.0
Amoxycillin 0 2.5 £0.015 ⁄ 1.0 0 0 £0.0075 ⁄ 0.03 0 0 0.25 ⁄ 1.0 0 21.7 2.0 ⁄ 8.0
Cefaclor 2.5 14.6 0.5 ⁄>8.0 0.9 0.6 0.5 ⁄ 1.0 35.0 45.0 2.0 ⁄>8.0 0 100 >8.0 ⁄>8.0
Cefuroxime 0.5 13.6 £0.015 ⁄ 4.0 0 0.6 £0.015 ⁄ 0.03 5.0 30.0 0.25 ⁄ 4.0 2.1 97.9 8.0 ⁄ 8.0
Ceftriaxone 5.0 0.8 0.015 ⁄ 1.0 0 0 0.015 ⁄ 0.03 10.0 0 0.12 ⁄ 1.0 38.3 6.4 1.0 ⁄ 2.0
Erythromycin 0.3 13.3 0.03 ⁄ 16.0 0.3 5.4 0.03 ⁄ 0.12 0 45.0 0.06 ⁄>16.0 0 55.3 8.0 ⁄>16.0
Clarithromycin 0.3 12.5 0.03 ⁄>8.0 0 5.1 0.03 ⁄ 0.06 0 40.0 0.03 ⁄>8.0 2.1 53.2 >8.0 ⁄>8.0
Azithromycin 0.3 12.5 0.06 ⁄>16.0 0 5.1 0.03 ⁄ 0.12 0 40.0 0.06 ⁄>16.0 2.1 53.2 >16.0 ⁄>16.0
Clindamycin 0 12.5 0.03 ⁄ 8.0 0 4.5 0.03 ⁄ 0.12 0 45.0 0.06 ⁄>8.0 0 55.3 >8.0 ⁄>8.0
Ciproﬂoxacinb 0 6.5 2.0 ⁄ 2.0 0 4.5 2.0 ⁄ 2.0 0 10.0 2.0 ⁄ 2.0 0 19.1 2.0 ⁄>4.0
Tetracycline 0.7 23.4 0.25 ⁄ 32.0 0.9 17.5 0.25 ⁄ 16.0 0 55.0 16.0 ⁄>32.0 0 51.1 16.0 ⁄>32.0
Co-trimoxazole 17.0 30.7 0.5 ⁄ 16.0 19.0 21.2 0.5 ⁄ 8.0 10.0 70.0 8.0 ⁄>16.0 6.3 80.9 8.0 ⁄>16.0
Rifampicin 0.5 0.5 0.03 ⁄ 0.12 0.3 0 0.03 ⁄ 0.12 0 10.0 0.03 ⁄ 0.12 2.1 0 0.03 ⁄ 0.12
PSP, penicillin-susceptible pneumococci; PIP, penicillin intermediately-susceptible pneumococci; PRP, penicillin-resistant pneumococci; %I, percentage of intermediately-
susceptible isolates; %R, percentage of resistant isolates.
aMIC50 ⁄MIC90 (mg ⁄L).
bPneumococci with ciproﬂoxacin MICs ‡4 mg ⁄L were regarded as resistant to this antibiotic.
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increased to 15.6% and 16.8% in 2003 and 2004,
respectively. There were differences in levels of
resistance to other antibiotics among BLNAS
isolates, BLPAR isolates and isolates with modi-
ﬁed PBPs. For example, the MIC50 and MIC90
values of cefuroxime and amoxycillin–clavulanic
acid for isolates with modiﬁed PBPs were four-
fold higher than those for BLNAS isolates. These
isolates were also less susceptible to co-trimoxaz-
ole (22.2%) than were BLNAS isolates (61.3%;
p <0.0001) or BLPAR isolates (80.7%; p <0.0001).
Resistance to tetracycline was found more often
among BLPAR isolates (22.6%) than among
BLNAS isolates (0.7%; p <0.0001) or among
isolates with modiﬁed PBPs (2.2%; p <0.001).
PFGE analysis classiﬁed 45 isolates with altered
PBPs into 15 PFGE types, including eight types
with one representative, four types with two
representatives, and one type with three repre-
sentatives. Two predominant PFGE types (A and
C), with four and six sub-types, contained 15 and
ten representatives, respectively. Eleven isolates
belonging to three sub-types of PFGE type A were
isolated in a single centre during 2003–2004,
although other PFGE types were also present.
The BLPACR Hib isolate had a unique PFGE
pattern.
S. pyogenes
The highest proportion (45.7%) of S. pyogenes
isolates was cultured from patients aged
<17 years. However, most infections in this group
affected children aged 3–8 years (n = 87, 63.0%),
followed by children aged 9–16 years (31.2%) and
children aged <3 years (5.8%). All 302 isolates of
S. pyogenes tested were susceptible to penicillin,
with MIC50 and MIC90 values of 0.0075 and
0.015 mg ⁄L, respectively. Of these, 20.9%, 8.9%
and 4.6% were resistant to tetracycline, erythro-
mycin and clindamycin, respectively. In the
group of 27 erythromycin-resistant isolates, 14
(51.9%) had the cMLSB phenotype, nine (33.3%)
had the iMLSB phenotype, and four (14.8%) had
the M phenotype. Resistance to tetracycline was
more prevalent in the iMLSB group (88.9%) than
in the cMLSB group (14.3%), whereas all isolates
with the M phenotype were sensitive to tetra-
cycline. Resistance to clindamycin was observed
exclusively in cMLSB isolates.
M. catarrhalis
In the group of M. catarrhalis isolates, 91.4% were
found to produce b-lactamase and this proportion
was similar in all 3 years studied.
DISCUSSION
During the past decade, increasing numbers of
PRP in some countries have resulted in the
limited use of penicillin as the antibiotic of choice
for the empirical treatment of diseases in which
pneumococci are strongly implicated as an
Table 3. MIC distributions (mg ⁄L) of b-lactam antibiotics for Haemophilus inﬂuenzae isolates (n = 344)
Antibiotics £0.0037 0.0075 0.015 £0.03 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 >16 %Sa
Ampicillin
BLNAS (n = 269) 2 6 79 117 42 23 100
BLPAR (n = 31a) 2 9 20 0
PBPs-mod (n = 45) 17 27 1 97.8
Amox ⁄ clav
BLNAS 5 9 22 101 89 20 18 5 100
BLPAR 14 15 2 100
PBPs-mod 2 2 12 12 9 8 100
Cefaclor
BLNAS 11 59 99 72 20 2 6 97.0
BLPAR 1 2 9 14 2 1 2 90.3
PBPs-mod 2 19 16 5 3 82.2
Cefuroxime
BLNAS 3 34 147 64 19 2 100
BLPAR 1 6 14 8 2 100
PBPs-mod 3 16 21 4 1 97.5
Ceftriaxone
BLNAS 161 13 94 1 100
BLPAR 23 2 6 100
PBPs-mod 6 25 7 2 4 1 100
%S, percentage of susceptible isolates; BLNAS, b-lactamase-negative ampicillin-susceptible isolates; BLPAR, b-lactamase-positive ampicillin-resistant isolates; PBPs-mod,
isolates with modiﬁed penicillin-binding proteins, including 44 low-BLNAR (b-lactamase-negative ampicillin-resistant isolates) and one low-BLPACR isolate (N.B. the low-
level BLPACR isolate appears in two categories, i.e. BLPAR and PBPs-mod); Amox ⁄ clav, amoxycillin–clavulanic acid.
aIncluding one low-level BLPACR (b-lactamase-positive, amoxycillin–clavulanic acid-resistant) isolate.
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aetiological agent [3,14]. In the present study,
16.8% of pneumococci were found to be PNSP,
which is a proportion similar to that reported in
previous studies from Poland [15,16], but slightly
higher than in Polish LRTIs isolates reported to
the Alexander Project between 1998 and 2000
(12.6%) [3]. The prevalence of PNSP in Poland is
higher than that in some neighbouring countries,
e.g., Germany (5.9%), the Czech Republic (6.2%)
and Russia (6.2%), but lower than that in Slovakia
(35.4%) and generally in western Europe (22.2%)
and the USA (37.0%) [3]. Although the percentage
of PNSP was stable during the study period, there
was a considerable increase in the proportion of
PRP among PNSP, from 50% to 83.3%, a ﬁnding
that has also been reported from other studies
[17–19]. This change in proportions is of great
concern, since LRTIs caused by PRP, in contrast to
those caused by penicillin intermediately-resist-
ant pneumococci, cannot be treated effectively by
penicillins [6]. Additionally, PRP are often multi-
drug-resistant, and this phenomenon further lim-
its the available therapeutic options [14,20]. In the
present study, an increase in resistance to other
b-lactams, macrolides, clindamycin, co-trimoxa-
zole, ciproﬂoxacin and newer quinolones was
found in comparison with previous studies [3,21],
and this rise was associated with an increasing
proportion of PRP. The study revealed that the
least active antimicrobial agent against pneumo-
cocci and H. inﬂuenzae was co-trimoxazole. This
may reﬂect the very high consumption of this
compound as a ﬁrst-line drug for the empirical
therapy of respiratory tract infections in Poland
(unpublished data from the Ofﬁce for Registration
of Medicinal Products, Medical Devices and
Biocidal Products).
The most unexpected ﬁndings concerned the
H. inﬂuenzae isolates, in which resistance to
b-lactams may be associated with either
b-lactamase production (most commonly) or
altered PBPs, or both [22]. Isolates with altered
PBPs have been observed increasingly, despite
being difﬁcult to detect in the laboratory [23–26].
Production of b-lactamase in the current 3-year
study was found in 9.0% of the isolates, which is
only slightly higher than the proportion reported
previously [27]. This overall percentage places
Poland among countries with low levels of amp-
icillin resistance, which is typical for eastern
Europe (6.4%) [3]. However, there was an increase
in BLPAR isolates to 16.8% during the last year of
the study. Recently, a higher proportion of BLPAR
isolates recovered from respiratory tract infections
in Polish children (24%) was also reported,
although this encompassed isolates from only
one region [16]. Although, globally, b-lactamase
production remains the most important mechan-
ism of resistance to amino-penicillins in H. inﬂu-
enzae, isolates with modiﬁcations in PBPs were
more prevalent in the present study (13.1%). An
even higher proportion of BLNAR isolates was
detected during the study conducted by Fluit et al.
[23], in which Poland had the highest rate of
BLNAR isolates from respiratory tract infections in
Europe (20%). Moreover, this previous report,
albeit based on a small number of isolates, showed
an increase in the prevalence of BLNAR isolates in
Poland, from 4.0% in 1997–1998 to 20% in 2002–
2003 [23]. A rising trend was also observed during
the present study, with the prevalence of isolates
with altered PBPs having increased three-fold by
the third year. There have also been reports from
other countries, e.g., France, Spain and, especially,
Japan (meningitis isolates), in which 18.9%, 9.3%
and 55.4% of H. inﬂuenzae isolates, respectively,
had changes in PBPs, with or without production
of b-lactamase [24–26].
The present data indicated that all isolates with
altered PBPs were of the low-level BLNAR or
low-level BLPACR types, and their detection was
possible only by PCR. Although elevated MIC50 ⁄
MIC90 values for low-level BLNAR isolates, in
comparison with BLNAS isolates, were observed
for all b-lactams tested, all low-level BLNAR
isolates had ampicillin MICs £1 mg ⁄L and, as
such, were classiﬁed as susceptible to this antibi-
otic according to CLSI criteria. However, it is
known that some isolates of H. inﬂuenzae with
ampicillin MICs of 0.5–2.0 mg ⁄L also exhibit
changes in PBPs [26,28]. Additionally, even if
MIC values are the same as those of BLNAS
isolates, the bactericidal effect of b-lactams
against low-level BLNAR strains possessing
altered PBP genes may be decreased [11]. There-
fore, it is important to monitor both BLNAR and
low-level BLNAR isolates that, despite their
apparent susceptible phenotype, demonstrate
changes in PBPs, indicating a stepwise acquisition
of resistance similar to that seen in S. pneumoniae
[28]. It is also necessary to reconsider changes in
laboratory procedures to include PCR or any
other methods that allow identiﬁcation of
BLNAR, low-level BLNAR, BLPACR and
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low-level BLPACR isolates, and to re-evaluate the
interpretation of susceptibility tests in order to
minimise the risk of treatment failure.
PFGE analysis revealed that the population of
isolates with altered PBPs in Poland is diverse, as
has been described previously for non-typeable
BLNAR isolates [29–31]. However, the identiﬁca-
tion of isolates with the same or very similar
PFGE patterns, not only from patients attending
the same hospital, but also from different parts of
the country, suggests possible clonal spread of
isolates with altered PBPs, as has been observed
previously [32].
Currently, S. pyogenes isolates are universally
susceptible to penicillin and, as expected, all
isolates of S. pyogenes tested during this survey
were highly susceptible to this antibiotic. Tetra-
cycline was the least active antibiotic against
S. pyogenes, as was also found in a previous study
of S. pyogenes isolates in Poland, although the
proportion of resistant isolates was only half that
in the present study [35]. However, this discrep-
ancy is a consequence of the fact that only about
50% of isolates were recovered from throat swabs
in the previous study [33]. The present study
found that <9% of isolates were resistant to
erythromycin, but among these, isolates with the
cMLSB phenotype were most common. Previ-
ously, erythromycin resistance reached 12%, but
with iMLSB as the most common phenotype [33].
Thus, it seems that the level of erythromycin
resistance in Poland is lower than in some other
countries, e.g., Spain (21.7%) and Greece (24%),
but is higher than in the USA (6.8%) [34–36].
The prevalence of b-lactamase-producing
M. catarrhalis isolates was >90% and did not
change during the study period. A similar pro-
portion was also found in a previous Polish study
[27], in M. catarrhalis isolates collected as part of
the Alexander Project (92.1%) in 1998–2000, and
in Canadian isolates (92.4%) collected in 1997–
2002 [3,37].
Following its initiation in 1992, the Alexander
Project was pivotal in deﬁning the role of global
surveillance of antimicrobial susceptibility pat-
terns among common respiratory pathogens [38].
However, only one, or very few, national centres
are involved in large international projects, and
therefore local and regional variations may not be
described adequately. For this reason, national
and local multicentre surveys, such as the present
study, are still required.
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